Supplementary Tables S1-S12 from Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy

Table S1. Genes included in the targeted next-generation sequencing HNSCC gene panel. Table S2. Compounds (n=220) and their drug classes/targets used in the drug screen. Table S3. qPCR primers and qPCR vs GE_microarray correlation. Table S4. Drug sensitivity scores (DSS) of the 220 compounds across 45 UT-SCC HNSCC cell lines. Table S5. All coding mutations found in 45 UT-SCC HNSCC cell lines by targeted sequencing of 694 genes. Table S6. Copy number alterations (CNA) found in 45 UT-SCC HNSCC cell lines. Table S7. Association between mutations and DSS. Table S8. Significant CNA-Drug associations. Table S9. Genes whose amplification is associated with concomitant overexpression. Table S10. Genes whose deletion is associated with concomitant underexpression. Table S11. Significant CNA_gene expression_DSS integration results. Table S12. Gene signatures associated with response to mTOR, MEK and EGFR inhibitors.